Neurological long COVID in the outpatient clinic: Is it so long?

Publication date: Mar 01, 2025

Neurological involvement in long COVID (coronavirus disease 2019) is well known. In a previous study we identified two subtypes of neurological long COVID, one characterized by memory disturbances, psychological impairment, headache, anosmia and ageusia, and the other characterized by peripheral nervous system involvement, each of which present a different risk factor profile. In this study, we aimed to clarify the persistence of neurological long COVID symptoms with a significantly longer term follow-up. We prospectively collected data from patients with prior COVID-19 infection who showed symptoms of neurological long COVID. We conducted a descriptive analysis to investigate the progression of neurological symptoms over time at 3-, 6-, 12-, and 18-month follow-ups. We performed a k-means clustering analysis on the temporal evolution of the symptoms at 6, 12, and 18 months. Finally, we assessed the difference between the recovery course of vaccinated and non-vaccinated patients by computing the cumulative recovery rate of symptoms in the two groups. The study confirmed the presence of two subtypes of neurological long COVID. Further, 50% of patients presented a complete resolution of symptoms at 18 months of follow-up, regardless of which subtype of neurological long COVID they had. Vaccination against SARS-Cov-2 appeared to imply a higher overall recovery rate for all neurological symptoms, although the statistical reliability of this finding is hampered by the limited sample size of the unvaccinated patients included in this study. Neurological long COVID can undergo complete resolution after 18 months of follow-up in 50% of patients and vaccination can accelerate the recovery.

Open Access PDF

Concepts Keywords
Complete Adult
Coronavirus Aged
Covid Ambulatory Care Facilities
Month Anosmia
Outpatient clustering
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
COVID‐19
Disease Progression
Female
Follow-Up Studies
Humans
Male
Middle Aged
Nervous System Diseases
neurological long COVID
Post-Acute COVID-19 Syndrome
Prospective Studies
recovery rate
SARS-CoV-2
vaccination

Semantics

Type Source Name
disease MESH long COVID
disease MESH coronavirus disease 2019
disease MESH anosmia
disease MESH ageusia
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH Infectious Diseases
disease IDO acute infection
drug DRUGBANK Heparin
disease IDO algorithm
disease MESH memory disorder
disease MESH complications
disease MESH Underweight
disease MESH Overweight
disease MESH Pneumonia
disease IDO symptom
drug DRUGBANK Oxygen
drug DRUGBANK Trestolone
disease MESH Vertigo
disease MESH Stroke
disease MESH neurological disorder
disease MESH inflammation
disease IDO intervention
drug DRUGBANK Ademetionine
drug DRUGBANK Aloe Vera Leaf

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *